When Steele, Richardson and Olszewski described Progressive Supranuclear Palsy in Archives of Neurology in 1964, it was thought to be a rare disease. Recent pathological studies of large numbers of patients diagnosed as having Parkinson's disease in life have highlighted the fact that at least one in ten of such cases have some other condition. Progressive Supranuclear Palsy is one of the commonest alternative diagnoses. This book is therefore a timely review of present understanding of Progressive Supranuclear Palsy. Much has been learnt about this sporadic illness of middle and late life although its cause remains unknown, and its treatment continues to be difficult. The Editors have selected a team of authors who review the clinical aspects, neuro-imaging find ings, neuropathology, neurochemistry, epidemiology, and therapy of Progres sive Supranuclear Palsy. All are to congratulated on producing an excellent and detailed picture of contemporary knowledge of the condition. Anyone interested in Progressive Supranuclear Palsy cannot do better than to start by reading this book. It is to be hoped that it will prompt further investigation to establish its cause and cure. C. D. MARSDEN, London Preface Progressive Supranuclear Palsy (PSP) is a neurodegenerative disorder charac terized clinically by the appearance of a supranuclear gaze palsy and extra pyramidal features which include bradykinesia and axial dystonia. Postural instability and falls and frontal-type behavioural and cognitive disturbances complete the clinical picture of this progressive disorder."

The Handbook of Clinical Neurology Vol 100: Hyperkinetic Movement Disorders discusses hyperkinetic disorders related mainly to basal ganglia dysfunction and pathology. It contains 13 sections and 51 chapters written by authoritative and experienced investigators and clinicians in this extremely broad and diverse group of diseases and syndromes. The first section on choreoathetoid diseases and syndromes includes chapters on Huntington's disease and Huntington's disease look-alikes; spinocerebellar degenerations; neuroacanthocytosis; entatorubral-pallidoluysian atrophy; neuroferritinopathy; neurodegeneration with brain iron accumulation; mitochondrial disorders; acquired hepatocerebral degeneration; benign hereditary chorea; and "senile chorea." The remaining chapters focus on the abnormal involuntary movements associated with each disease or syndrome. These include immune-related chorea, vascular chorea, metabolic disturbances that can induce chorea, chorea in other medical settings (e.g., postpump chorea in children, cancer-related paraneoplastic syndromes), myoclonus, essential tremor, and dystonia, including dystonia plus syndromes. There are also chapters on tardive dyskinesia, unusual clinical syndromes, and tics and stereotyped movements in children. The text is a valuable resource for neurology and psychiatry residents, practicing neurologists and psychiatrists, and specialists in movement disorders.

Paediatric Movement disorders is a relatively new and exciting field of child neurology. This book represents the outcome of an international symposium organised as a forum of exchange between both adult and child neurologists. The contributions of highly qualified experts represent the 'state of the art' of this rapidly expanding field. A source of thought for progress in further understanding, it will prove to be a useful tool to both clinicians and scientists.

Patients with Parkinson's disease (PD) are known to suffer from motor symptoms of the disease, but they also experience non-motor symptoms (NMS) that are often present before diagnosis or that inevitably emerge with disease progression. The motor symptoms of Parkinson's disease have been extensively researched, and effective clinical tools for their assessment and treatment have been developed and are readily available. In contrast, researchers have only recently begun to focus on the NMS of Parkinson's Disease, which are poorly recognized and inadequately treated by clinicians. The NMS of PD have a significant impact on patient quality of life and mortality and include neuropsychiatric, sleep-related, autonomic, gastrointestinal, and sensory symptoms. While some NMS can be improved with currently available treatments, others may be more refractory and will require research into novel (non-dopaminergic) drug therapies for the future. Edited by members of the UK Parkinson's Disease Non-Motor Group (PD-NMG) and with contributions from international experts, this new edition summarizes the current understanding of NMS symptoms in Parkinson's disease and points the way towards future research.